Cosyntropin Dosing in Chronic Kidney Disease
No dose adjustment of cosyntropin is required for patients with chronic kidney disease, including those on dialysis—use the standard diagnostic dose of 250 µg IV or 1 µg IV depending on the test protocol.
Standard Dosing Protocol
The standard cosyntropin stimulation test uses 250 µg (0.25 mg) administered intravenously, with blood sampling at 0,30, and 60 minutes for cortisol measurement 1. An alternative low-dose protocol uses 1 µg IV with sampling at 0 and 30 minutes 1. Both protocols are designed to assess adrenal function and are not dependent on renal clearance mechanisms.
Why No Adjustment is Needed
Cosyntropin (synthetic ACTH 1-24) is a peptide hormone that:
- Acts directly on adrenal cortical receptors to stimulate cortisol release
- Is not primarily eliminated by the kidneys
- Functions as a diagnostic agent rather than a therapeutic medication requiring steady-state dosing
- Has a mechanism of action independent of renal function
The drug label confirms it is supplied as 0.25 mg per vial for IV or IM use 2, with no mention of renal dose adjustments—a standard omission that would be explicitly stated if adjustments were necessary.
Clinical Application in CKD
For patients with any stage of CKD (including eGFR <15 mL/min/1.73 m² or those on hemodialysis):
- Use the standard 250 µg dose for routine ACTH stimulation testing
- Timing relative to dialysis: Not specified in guidelines, as cosyntropin is not dialyzable and the test is brief (60 minutes maximum)
- No monitoring adjustments: Standard cortisol response criteria apply (peak cortisol >500-550 nmol/L or 18.1-20 µg/dL depending on assay) 1
Important Caveats
While cosyntropin itself requires no adjustment, be aware that:
- Many medications used in CKD patients do require dose adjustments, with antibiotics being the most commonly inappropriately dosed class (77% of dosing errors in one study) 3
- Polypharmacy is nearly universal in CKD (91% prevalence) 3, but this does not affect cosyntropin testing
- The test interpretation remains valid regardless of renal function, as it assesses adrenal reserve rather than drug clearance
The key principle: Cosyntropin is a diagnostic peptide hormone that stimulates a physiologic response—it is not renally cleared and therefore needs no dose modification in kidney disease.